Clinical trial
Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
NCT06781905 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
- Lead sponsor
- Hospices Civils de Lyon
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 16, 2025
- Completion date
- May 9, 2027
- Enrollment
- 20 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic lung cancer, metastatic lung cancer with alk/ros1 fusion